S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:OXFD - Oxford Immunotec Global Stock Price, Forecast & News

$17.28
-0.04 (-0.23 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$17.13
Now: $17.28
$17.49
50-Day Range
$14.95
MA: $16.35
$17.31
52-Week Range
$11.88
Now: $17.28
$18.60
Volume62,600 shs
Average Volume171,301 shs
Market Capitalization$457.00 million
P/E Ratio33.88
Dividend YieldN/A
Beta0.48
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.75 million
Cash Flow$0.67 per share
Book Value$8.12 per share

Profitability

Net Income$120.78 million

Miscellaneous

Employees215
Market Cap$457.00 million
Next Earnings Date3/9/2020 (Estimated)
OptionableNot Optionable

Receive OXFD News and Ratings via Email

Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter.


Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions

What is Oxford Immunotec Global's stock symbol?

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

How were Oxford Immunotec Global's earnings last quarter?

Oxford Immunotec Global PLC (NASDAQ:OXFD) announced its quarterly earnings data on Tuesday, November, 5th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.09. The business earned $21.20 million during the quarter, compared to analyst estimates of $20.23 million. Oxford Immunotec Global had a net margin of 199.21% and a return on equity of 15.77%. The company's revenue was up 31.7% on a year-over-year basis. During the same period last year, the firm posted ($0.13) EPS. View Oxford Immunotec Global's Earnings History.

When is Oxford Immunotec Global's next earnings date?

Oxford Immunotec Global is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Oxford Immunotec Global.

What price target have analysts set for OXFD?

2 brokerages have issued 12 month price targets for Oxford Immunotec Global's stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate Oxford Immunotec Global's stock price to reach $20.00 in the next year. This suggests a possible upside of 15.7% from the stock's current price. View Analyst Price Targets for Oxford Immunotec Global.

What is the consensus analysts' recommendation for Oxford Immunotec Global?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford Immunotec Global.

Has Oxford Immunotec Global been receiving favorable news coverage?

News headlines about OXFD stock have been trending somewhat negative on Wednesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Oxford Immunotec Global earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Oxford Immunotec Global.

Are investors shorting Oxford Immunotec Global?

Oxford Immunotec Global saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 364,400 shares, an increase of 5.6% from the October 31st total of 345,200 shares. Based on an average trading volume of 163,100 shares, the days-to-cover ratio is presently 2.2 days. Currently, 1.4% of the shares of the stock are sold short. View Oxford Immunotec Global's Current Options Chain.

Who are some of Oxford Immunotec Global's key competitors?

What other stocks do shareholders of Oxford Immunotec Global own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include Immunomedics (IMMU), Intel (INTC), AbbVie (ABBV), Gold Resource (GORO), Sangamo Therapeutics (SGMO), Centurylink (CTL), Adaptimmune Therapeutics (ADAP), Akorn (AKRX), Advanced Micro Devices (AMD) and Abraxas Petroleum (AXAS).

Who are Oxford Immunotec Global's key executives?

Oxford Immunotec Global's management team includes the folowing people:
  • Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 45)
  • Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 58)
  • Mr. Matthew T.E. McLaughlin, Chief Financial Officer (Age 42)
  • Mr. Stefan C. Linn, Chief Operating Officer (Age 54)
  • Ms. Karen C. Koski, VP of Strategy & Investor Relations

Who are Oxford Immunotec Global's major shareholders?

Oxford Immunotec Global's stock is owned by a number of of retail and institutional investors. Top institutional investors include Millennium Management LLC (4.97%), Endurant Capital Management LP (3.74%), Granahan Investment Management Inc. MA (3.07%), Man Group plc (2.78%), Essex Investment Management Co. LLC (0.48%) and Boston Advisors LLC (0.48%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.

Which institutional investors are selling Oxford Immunotec Global stock?

OXFD stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Essex Investment Management Co. LLC, Squarepoint Ops LLC and Campbell & CO Investment Adviser LLC. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global.

Which institutional investors are buying Oxford Immunotec Global stock?

OXFD stock was purchased by a variety of institutional investors in the last quarter, including Man Group plc, Endurant Capital Management LP, Millennium Management LLC, Boston Advisors LLC, Granahan Investment Management Inc. MA, California Public Employees Retirement System, Tocqueville Asset Management L.P. and Oppenheimer & Co. Inc.. View Insider Buying and Selling for Oxford Immunotec Global.

How do I buy shares of Oxford Immunotec Global?

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Oxford Immunotec Global's stock price today?

One share of OXFD stock can currently be purchased for approximately $17.28.

How big of a company is Oxford Immunotec Global?

Oxford Immunotec Global has a market capitalization of $457.00 million and generates $59.75 million in revenue each year. The company earns $120.78 million in net income (profit) each year or $0.51 on an earnings per share basis. Oxford Immunotec Global employs 215 workers across the globe.View Additional Information About Oxford Immunotec Global.

What is Oxford Immunotec Global's official website?

The official website for Oxford Immunotec Global is http://www.oxfordimmunotec.com/.

How can I contact Oxford Immunotec Global?

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]


MarketBeat Community Rating for Oxford Immunotec Global (NASDAQ OXFD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  241 (Vote Underperform)
Total Votes:  482
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: How mutual funds make money

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel